IRON Stock Analysis: Buy, Sell, or Hold?
IRON - Disc Medicine, Inc. Common Stock
$71.33
0.88 (1.25%)
▲
5d:
+2.15%
30d:
+6.75%
90d:
+19.66%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When IRON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IRON shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IRON shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IRON is currently trading at $71.33, which is considered extended relative to its 30-day fair value range of $66.88 to $70.77.
Technical Outlook: Technically, IRON is showing sideways momentum. The price is approaching resistance at $72.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IRON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $101.55 (+44.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IRON is showing sideways momentum. The price is approaching resistance at $72.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IRON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $101.55 (+44.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$66.88 -
$70.77
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 44.1% below Wall St target ($101.55)
Trading Range Analysis
30-Day Trading Range
$66.88 -
$70.77
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$4.07
(5.7%)
Support & Resistance Levels
Support Level
$67.02
Resistance Level
$72.83
Current Trend
Sideways
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.29
Wall Street Target
$101.55
(+44.1%)
Share & Embed Analysis
Last updated: June 24, 2026 2:53 PM ET
Data refreshes hourly during market hours. Next update: 3:53 PM
Data refreshes hourly during market hours. Next update: 3:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Jean M Franchi
SELL
6257 shares
2026-04-14
William Jacob Savage
SELL
5731 shares
2026-04-13
Jean M Franchi
SELL
400 shares
2026-04-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 60 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 69 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
Advanced IRON Option Strategies
Professional options setups generated by AI based on today's IRON price and gamma walls.
